Biovica International AB Email Format
Medical Equipment ManufacturingUppsala, Sweden11-50 Employees
Biovica International AB develops and commercializes blood-based biomarker assays intended to monitor responses to modern cancer therapies and help predict patient outcomes. Its DiviTum TKa assay measures cell proliferation and has demonstrated potential for early assessment of treatment effectiveness in various clinical trials. The company collaborates with leading cancer institutes and pharmaceutical developers bringing next-generation therapies to market, and maintains a CLIA-certified laboratory in the United States that provides the DiviTum TKa test as a service. In Europe, DiviTum TKa is CE-labeled and MPA-registered, and Biovica maintains ISO 13485 certification for its quality management systems. The company is based in Uppsala, Sweden, and operates as a relatively small to mid-sized player in the medical equipment manufacturing sector. A notable recent development is Biovica's 2025 collaboration with Outcomes4Me to support personalized navigation for cancer patients.